|Videos|June 6, 2017
Dr. West on Emerging Changes in the Field of EGFR-Mutant NSCLC
Author(s)H. Jack West, MD
H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses some potential emerging changes coming to the field of EGFR-mutant non–small cell lung cancer (NSCLC), including next-generation EGFR inhibitors such as osimertinib (Tagrisso) that is now being explored in the FLAURA trial as a frontline treatment for these patients.
Advertisement
H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses some potential emerging changes coming to the field of EGFR-mutant non—small cell lung cancer (NSCLC), including next-generation EGFR inhibitors such as osimertinib (Tagrisso), which is now being explored in the FLAURA trial as a frontline treatment.
<<<
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
2
As ADC Options Expand, Sequencing and Toxicity Management Become the Next Challenges in Gynecologic Oncology
3
MANGROVE Trial Shows Improved Efficacy With Zanubrutinib Plus Rituximab vs Chemo in MCL
4
Mayo Clinic Researchers Uncover Critical Link in the Immune Response to Cancer
5